Table 2 Efficacy of second line H. pylori eradication therapy.
From: Efficacy of Helicobacter pylori eradication therapies: a single centre observational study
Regimen | Number | Treatment | Perecent | 95% CI |
|---|---|---|---|---|
treated | successful | success | ||
7 days | ||||
PPI | 27 | 19 | 70% | 52.8–87.2*$ |
nitroimidazole | ||||
tetracycline 500 mg qid | ||||
DCB 240 mg bid | ||||
7 days | ||||
PPI | 7 | 2 | 28% | 0–61 |
amoxicillin 1 g bid | ||||
nitroimidazole | ||||
7 days | ||||
PPI | 1 | 0 | 0% | - |
clarithromycin 500 mg bid | ||||
nitroimidazole | ||||
7 days | ||||
PPI | 8 | 4 | 50% | 15.4–84.6 |
amoxicillin 1 g bid | ||||
clarithromycin 500 mg bid | ||||
7 days | ||||
RBC 400 mg bid | 18 | 13 | 73% | 52.4–93.6*$ |
amoxicillin 1 g bid | ||||
clarithromycin 500 mg bid | ||||
7 days | ||||
RBC 400 mg bid | 5 | 4 | 80% | 45–100 |
tetracycline 1 g bid | ||||
nitroimidazole |